Pharmaceuticals

Pfizer

Salesforce

Conference Minutes

INFA

VEEV

TWTR

08391

4502

Below is Dolphin Research's Trans of $Salesforce(CRM.US) FY26 Q4 earnings call.For our earnings analysis, cf. 'Salesforce: The AI replacement thesis sweeps the field — has the SaaS leader been cast aside?'Key takeaways recap1) Q1 guidance: revenue of $11.03–11.08bn, implying reported growth of ~12–13%.Management also guides Q1 CRPO to grow ~14% YoY on a reported basis ...

ServiceNow

Informatica

Veeva Systems -CL

Sunrun

AstraZeneca PLC

AstraZeneca

Twitter

CORNERSTONE TEC

Takeda Pharmaceutical Co. Ltd.

CRM Trans: Organic rev. growth to re-accelerate in H2 FY

---

FDA Approves Pfizer's HYMPAVZI for Additional Hemophilia A or B Patient Groups

Pfizer Reports Vesper-1 2b Data: Near 16% Weight Loss, Plans 10 Phase 3 Trials

Pfizer Emphasizes Oncology Strategy: Acquires Seagen to Expand Pipeline and Commits to AI Transformation by 2027

Pfizer Announces Clinical Trial Update for Novel Tumor Drug PF-08634404

Chai Discovery Announces Licensing Agreement with Pfizer to Accelerate Drug Discovery Using AI

Innovent Biologics and Pfizer Sign $10.5 Billion Global Strategic Cooperation, Pioneering Co-Co Model for Chinese Drug Export

Innovent Biologics and Pfizer Reach $10.5 Billion Global Oncology Collaboration Agreement

Pfizer's Cresemba Receives NMPA Approval for New Pediatric Indication

S&P Global upgrades Pfizer to 'Buy', sets target price at $29.19

Pfizer China and Meixin Health Reach Strategic Cooperation to Accelerate Innovative Drug Landing on May 21

Pfizer and Sarah Cannon Institute Announce Strategic Oncology Research Collaboration

Marble Harbor Increases Pfizer Stake by 13.4% to $11.1M as Q4 Earnings Beat Expectations

Pfizer Advances Key Pediatric Pneumococcal Vaccine Project Following Strong Phase II Results

Canada Post Increases Pfizer Stake by 13.8% in Q4 to $9.7M; Pfizer Earnings Beat but Stock Dips on Concerns

Pfizer Average Price Target Cut to $28.88, Analysts Maintain Hold Rating

Pfizer Advances Planning for Phase III RSVpreF Vaccine Study in Japan

European Commission Approves Pfizer's HYMPAVZI for Hemophilia Patients

Pfizer Reports Robust Q1 Earnings, Stock Lags Behind S&P 500

CStone Pharmaceuticals Reaps Significant Benefits from 707 Authorization Deal with Pfizer

Pfizer Clarifies Its COVID-19 Vaccine Does Not Contain Hantavirus

CCSC Tech

Youlife

Core AI

Regentis Biomaterials

Epsium Enterprise

Autozi Internet Tech Global

Leslies

Mega Matrix

eLong Power

Smart Logistics Global

Pfizer Inc. (PFE.US) Q4 2025 Earnings Conference Call

Pfizer Inc. (PFE.US) Q3 2025 Earnings Conference Call

Pfizer Inc. (PFE.US) Q1 2025 Earnings Conference Call

Pfizer Inc. (PFE.US) Fourth Quarter 2024 Earnings Conference Call

Pfizer Inc. Pharmaceutical Company (PFE.US) 2024 Third Quarter Earnings Conference Call

A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

Pharmaceutical Technology

Pfizer’s Hympavzi secures FDA expanded indications for haemophilia

Pfizer reported Phase 2b data for its investigational obesity drug berobenatide, showing a 15.9% non-placebo-adjusted weight loss. The company plans to advance multiple Phase 3 studies in 2026 for chronic weight management and related comorbidities. Concurrently, the FDA expanded HYMPAVZI's indication for hemophilia patients. Despite these developments, Pfizer shares declined by approximately 1.3%.

- Pfizer Inc. shares fell nearly 1% following the release of Phase 2b data for berobenatide, showing a 15.9% non-placebo-adjusted weight loss in participants.  
- The company is advancing 10 Phase 3 studies in 2026 to enhance its obesity treatment market position, with the pivotal VESPER-6 study now open for enrollment.  
- Additionally, the FDA approved an expanded indication for Pfizer’s HYMPAVZI therapy for hemophilia A or B in certain pediatric populations.

benzinga_article

INNOVENT BIO

Reddit

Pfizer's Obesity Drug Shows 16% Weight Loss In Phase 2b Study

Pfizer announced that the FDA has approved an expanded indication for HYMPAVZI (marstacimab-hncq) to treat hemophilia A and B. The approval covers adults and pediatric patients aged 6 and older, including those with inhibitors. This expansion allows for routine prophylaxis to prevent bleeding episodes via once-weekly subcutaneous administration, supported by Phase 3 trial results demonstrating significant reductions in annualized bleeding rates.

- Pfizer, Inc. announced FDA approval for HYMPAVZI (marstacimab-hncq) to treat hemophilia A or B in patients aged 12 years and older with inhibitors, as well as pediatric patients ages 6 to 11.  
- The drug is indicated for routine prophylaxis to prevent bleeding episodes and offers a once-weekly subcutaneous administration without routine lab monitoring.  
- Approval was supported by Phase 3 trial results showing a 93% reduction in annualized bleeding rates compared to traditional treatments.

nasdaq

Nasdaq

Pfizer Says FDA Approves Expanded HYMPAVZI Indication For Hemophilia A And B

Pfizer(PFE.US)

Pfizer’s Hympavzi secures FDA expanded indications for haemophilia

Pfizer's Obesity Drug Shows 16% Weight Loss In Phase 2b Study

Pfizer Says FDA Approves Expanded HYMPAVZI Indication For Hemophilia A And B